NIH Research Response to the Threat of Bioterrorism

- Biodefense Research Activities
- Coordination of Research Activities
- Research and Development Priorities Based on Threat Assessment

NIAID BIODEFENSE Preparing Through Research
NIAID Strategic Plan for Biodefense Research
NIAID Biodefense Research Agenda for CDC Category A Agents
NIAID Biodefense Research Agenda for Category B and C Priority Pathogens
January 2003
NIAID Biodefense Research Agenda for CDC Category A Agents
Progress Report
August 2003
NIAID Biodefense Research Agenda for Category B and C Priority Pathogens
Progress Report
June 2004
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases

Expansion of Biodefense Research Capacity



- National Biocontainment Laboratories (BSL4) - 2
- Regional Biocontainment Laboratories (BSL3) - 9
- Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research - 8
- New NIH Facilities - 4

NIH Biodefense Research and Development Pathway



Countermeasure Development

- **New and Improved Vaccines**
  (smallpox, anthrax, Ebola, tularemia, plague)
- **Therapies**
  (smallpox and anthrax therapeutics, botulism antitoxins)
- **Diagnostics**

Coordination of Biodefense Activities

NIH

- NIH Biodefense Research Coordinating Committee → NIH Institutes and Centers

DHHS

- Office of the Assistant Secretary for Public Health Emergency Preparedness → NIH, FDA, CDC

Federal Government

- Homeland Security Council and National Security Council → Federal Agencies
  - DHS
  - HHS
  - DOD
  - Other relevant agencies

Research and Development Priorities Based on Threat Assessment

- CDC Category A, B, and C agents
- Department of Homeland Security (DHS)